Literature DB >> 1906932

Hyperprolactinemia in multiple sclerosis.

J Kira1, M Harada, Y Yamaguchi, N Shida, I Goto.   

Abstract

In order to clarify endocrine abnormalities due to hypothalamic involvement in multiple sclerosis (MS), serum prolactin levels were measured in 27 patients with MS and 22 healthy subjects. The presence of hypothalamic lesions was also studied by magnetic resonance imaging (MRI). Serum prolactin levels were found to be significantly higher in MS patients than in healthy controls in both sexes. Although only one patient had galactorrhea, one-third of the MS patients had mild to moderate hyperprolactinemia, which was a 4-13-fold increase over the mean value of healthy subjects. The results of thyrotropin-releasing hormone, sulpiride, L-DOPA and bromocriptine loading tests suggested a hypothalamic dysfunction, rather than pituitary prolactinoma in MS patients. Four of eight patients with hyperprolactinema had diencephalic hypothalamic lesion(s) contiguous with the third ventricle on the brain MRI, while none of the normoprolactinemic patients had any lesions in the diencephalon. All relapsing-remitting patients with hyperprolactinemia showed a rise in prolactin levels in the acute stage of the relapse and a decrease during the recovering stage and the following remission phase. Our findings suggest that latent hyperprolactinemia due to hypothalamic dysfunction occurs frequently in MS patients in relapse. The increase of serum prolactin is considered to be a sensitive indicator for hypothalamic lesions in MS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906932     DOI: 10.1016/0022-510x(91)90094-n

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  15 in total

1.  Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients.

Authors:  Hedi Orbach; Gisele Zandman-Goddard; Mona Boaz; Nancy Agmon-Levin; Howard Amital; Zoltan Szekanecz; Gabriella Szucs; Josef Rovensky; Emese Kiss; Andrea Doria; Anna Ghirardello; Jesus Gomez-Arbesu; Ljudmila Stojanovich; Francesca Ingegnoli; Pier Luigi Meroni; Blaz' Rozman; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

2.  Prolactin is Not Associated with Disability and Clinical Forms in Patients with Multiple Sclerosis.

Authors:  Wildéa Lice de Carvalho Jennings Pereira; Tamires Flauzino; Daniela Frizon Alfieri; Sayonara Rangel Oliveira; Ana Paula Kallaur; Andrea Name Colado Simão; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Neuromolecular Med       Date:  2019-08-31       Impact factor: 3.843

Review 3.  Dopamine, T cells and multiple sclerosis (MS).

Authors:  Mia Levite; Franca Marino; Marco Cosentino
Journal:  J Neural Transm (Vienna)       Date:  2017-03-10       Impact factor: 3.575

4.  Serum Prolactin Levels in Multiple Sclerosis, Neuromyelitis Optica, and Clinically Isolated Syndrome Patients.

Authors:  Recai Türkoğlu; Murat Giriş; Mehmet Gencer; Uğur Akcan; Arda Örçen
Journal:  Noro Psikiyatr Ars       Date:  2016-12-01       Impact factor: 1.339

5.  Longer T(2) relaxation time is a marker of hypothalamic gliosis in mice with diet-induced obesity.

Authors:  Donghoon Lee; Joshua P Thaler; Kathryn E Berkseth; Susan J Melhorn; Michael W Schwartz; Ellen A Schur
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-02       Impact factor: 4.310

6.  Multiple sclerosis attacks triggered by hyperprolactinemia.

Authors:  V Nociti; G Frisullo; T Tartaglione; A K Patanella; R Iorio; P A Tonali; A P Batocchi
Journal:  J Neurooncol       Date:  2009-12-03       Impact factor: 4.130

7.  The Level of Testosterone, Vitamin D, and Irregular Menstruation More Important than Omega-3 in Non-Symptomatic Women Will Define the Fate of Multiple Scleroses in Future.

Authors:  Shima Tavakol; Sahar Shakibapour; Sepideh Arbabi Bidgoli
Journal:  Mol Neurobiol       Date:  2016-12-13       Impact factor: 5.590

Review 8.  Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?

Authors:  Marco Cosentino; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-17       Impact factor: 4.147

9.  Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.

Authors:  V Larouche; J A Correa; P Cassidy; C Beauregard; N Garfield; J Rivera
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

Review 10.  Neuromyelitis optica: diagnosis, pathogenesis, and treatment.

Authors:  Bruce Cree
Journal:  Curr Neurol Neurosci Rep       Date:  2008-09       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.